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Summary
Activation of tyrosine kinase 2 (TYK2) contributes to the aberrant survival of T-cell acute 
lymphoblastic leukaemia (T-ALL) cells. Here we demonstrate the anti-leukaemic activity of a 
novel TYK2 inhibitor, NDI-031301. NDI-031301 is a potent and selective inhibitor of TYK2 that 
induced robust growth inhibition of human T-ALL cell lines. NDI-031301 treatment of human T-
ALL cell lines resulted in induction of apoptosis that was not observed with the JAK inhibitors 
tofacitinib and baricitinib. Further investigation revealed that NDI-031301 treatment uniquely 
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leads to activation of three mitogen-activated protein kinases (MAPKs), resulting in 
phosphorylation of ERK also termed MAPK1), SAPK/JNK (MAPK9/MAPK8) and p38 MAPK 
(MAPK14) coincident with PARP cleavage. Activation of p38 MAPK occurred within 1 h of 
NDI-031301 treatment and was responsible for NDI-031301-induced T-ALL cell death, as 
pharmacological inhibition of p38 partially rescued apoptosis induced by TYK2 inhibitor. Finally, 
daily oral administration of NDI-031301 at 100 mg/kg bid to immunodeficient mice engrafted 
with KOPT-K1 T-ALL cells was well tolerated, and led to decreased tumour burden and a 
significant survival benefit. These results support selective inhibition of TYK2 as a promising 
potential therapeutic strategy for T-ALL.
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Introduction
T-cell acute lymphoblastic leukaemia (T-ALL) is an aggressive haematological malignancy 
resulting from the transformation of T-cell progenitors and occurs in about 15% of paediatric 
and 25% of adult ALL cases. The prognosis of this disease has substantially improved due to 
the introduction of intensified chemotherapy, with cure rates in modern protocols reaching 
over 75% in children and about 50% in adults (Goldberg, et al 2003, Marks, et al 2009). 
Nevertheless, the clinical outcome of T-ALL patients with primary resistant or relapsed 
disease still remains poor (Goldberg, et al 2003, Oudot, et al 2008, Schrappe, et al 2012), 
and aggressive treatment regimens are often associated with severe acute toxicities and long-
term side effects, including the development of secondary tumours later in life. Thus, 
development of more effective and less toxic anti-leukaemic drugs have been the focus of 
research efforts in T-ALL (Aifantis, et al 2008).
We have previously demonstrated that tyrosine kinase 2 (TYK2) activation contributes to 
aberrant survival of human T-ALL cells (Sanda, et al 2013). TYK2 is a member of the 
Janus-activated kinase (JAK) tyrosine kinase family and our report was the first to implicate 
TYK2 as an oncogene in T-ALL. Indeed, our gene knockdown experiments showed TYK2 
dependency in 14 of 16 (88%) T-ALL cell lines and 5 of 8 (63%) patient-derived T-ALL 
cells tested (Sanda, et al 2013). In addition, pharmacological inhibition of TYK2 with a 
small-molecule pan-JAK inhibitor, JAK inhibitor I, induced apoptosis in multiple human T-
ALL cell lines (Sanda, et al 2013). Our results also showed that TYK2 promotes the survival 
of T-ALL cells by upregulating the anti-apoptotic protein BCL2 through phosphorylation 
and activation of STAT1 (Sanda, et al 2013). These findings establish TYK2 as a promising 
molecular target for the treatment of T-ALL.
Each of the four JAK family kinases (JAK1, JAK2, JAK3 and TYK2) associates with a 
distinct set of receptors. Receptor activation triggers receptor intracellular domain 
phosphorylation, creating docking sites for signal transducers and activators of transcription 
(STAT) proteins (Ghoreschi, et al 2009, Leonard and O'Shea 1998, Liu, et al 1998). STAT 
proteins are subsequently phosphorylated by the JAKs, form homodimers or heterodimers, 
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translocate to the cell nucleus, and mediate gene transcription. TYK2 is involved in receptor 
signalling mediated by inflammatory cytokines including the type-I interferons, interleukin 
(IL)-12 and IL-23 (Ihle, et al 1995, Leonard and O'Shea 1998, Liu, et al 1998). Therefore 
TYK2 kinase inhibitors are being developed as potential therapeutics for auto-immune 
inflammatory diseases, such as psoriasis and inflammatory bowel diseases (Liang, et al 
2013a, Liang, et al 2013b). However, generating kinase inhibitors with a high degree of 
TYK2 selectivity has posed a significant challenge due to the high sequence homology of 
the active site among the JAK family kinases. TYK2 specificity is important for clinical 
application of TYK2 kinase inhibitors, because Tyk2 knockout mice are viable with normal 
blood cell counts (Ghoreschi, et al 2009, Karaghiosoff, et al 2000, Shimoda, et al 2000), 
whereas deficiency of Jak3 results in severe combined immunodeficiency in mice, and Jak1 
or Jak2 knockout mice show perinatal lethality (Ghoreschi, et al 2009). A loss-of-function 
mutation in the TYK2 gene was identified in a patient with hyperimmunoglobulin E 
syndrome (Minegishi, et al 2006), a primary immunodeficiency characterized by elevated 
serum immunoglobulin E. However, an additional seven individuals with homozygous null 
mutations of TYK2 did not have hyperimmunoglobulin E syndrome, but rather exhibited 
increased susceptibility to mycobacteria or viral infections due to impaired responses to 
IL-12 and IFN-α/β (Kreins, et al 2015). Thus, genetic evidence suggests that 
pharmacological inhibition of TYK2 should not result in acute toxicity in human patients, 
but careful monitoring for viral or mycobacterial infections would be warranted in patients 
treated for prolonged periods.
Here we describe the identification and characterization of the novel highly potent and 
selective TYK2 inhibitor, NDI-031301. We show that this inhibitor has significant anti-
leukaemic activity against human T-ALL cell lines in vitro due to its ability to efficiently 
induce apoptosis in these cells. The inhibitor is orally bioavailable and xenograft studies 
with a human T-ALL cell line KOPT-K1 showed that it has significant anti-tumour activity 
in vivo without appreciable side effects. Thus, our preclinical findings warrant further testing 
of NDI-031301 or related compounds as promising drugs for targeted treatment of T-ALL, 
with the expectation that effective inhibition of the TYK2 pathway would eventually be 
combined with other anti-leukaemic agents in novel strategies of combination therapy.
Materials and methods
Reagents
NDI-031301 was provided by Nimbus Therapeutics (Cambridge, MA, USA). Tofacitinib 
baricitinib, trametinib, SP600125, and SB203580 were purchased from Selleck Chemicals 
(Houston, TX, USA).
Cell culture
All human T-ALL cell lines (KOPT-K1, DU.528, HPB-ALL and SKW-3) were obtained 
from the American Type Culture Collection (ATCC; Manassas, VA, USA) or Deutsche 
Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ; Braunschweig, 
Germany). Ba/F3 derivatives expressing various oncogenic fusion kinases, namely, TEL-
ABL (ETV6-ABL1), TEL-JAK1 (ETV6-JAK1), TEL-JAK2 (ETV6-JAK2), and TEL-JAK3 
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(ETV6-JAK3), were obtained from Dr. Richard Morrigl and were described previously 
(Lacronique, et al 2000). Ba/F3 cells transformed by TEL-TYK2 were generated with the 
pBabe-Neo retroviral vector expressing ETV6 (TEL)-TYK2 cDNA (Lacronique, et al 2000), 
which was obtained from Dr. Olivier A. Bernard. These cells were maintained in 
RPMI-1640 medium (GIBCO, Waltham, MA, USA) supplemented with 10% fetal bovine 
serum (Sigma-Aldrich, St. Louis, MO, USA) and 1% penicillin/streptomycin (Invitrogen, 
Waltham, MA, USA).
shRNA knockdown experiments
All shRNA constructs cloned into the lentiviral vector pLKO.1-puro were obtained from the 
RNAi Consortium (Broad Institute, Cambridge, MA, USA). Target sequences for each 
shRNA are listed in Table SI. Each construct was cotransfected into HEK293T cells with the 
packaging plasmid psPAX2 and envelope plasmid pMD2.G using FuGENE 6 reagent 
(Roche, Basel, Switzerland). Supernatants containing the lentivirus were collected and 
filtered through a 0.45-μm cellulose acetate membrane filter. T-ALL cell lines were then 
infected with lentivirus in the presence of polybrene (8 μg/ml) and HEPES (10 mM) by 
centrifugation at 2,500 rpm for 1.5 h at 30°C, and the infected cells were selected by 
puromycin for at least 36 h.
Cell viability analysis
The Cell Titer Glo assay (Promega, Fitchburg, WI, USA) was used to assess relative cell 
viability upon treatment. Cells were plated at a density of 5000 - 10000 cells per well in a 
96-well plate and incubated with dimethylsulfoxide (DMSO) or increasing concentrations of 
inhibitor. The relative cell viability was measured after different treatment intervals and 
reported as a percentage of the DMSO control. The concentration of inhibitor required for 
50% inhibition of cell viability (IC50) was determined with GraphPad Prism 6.02 (GraphPad 
Software, La Jolla, CA, USA).
Apoptosis and cell cycle analysis
Both the terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labeling (TUNEL) 
assay and propidium iodide (PI) staining were performed with the APO-BrdU™ TUNEL 
assay kit (Invitrogen, Waltham, MA, USA), according to the manufacturer’s 
recommendation. Briefly, 2 × 106 cells of each treated sample were fixed with 1% 
paraformaldehyde in phosphate-buffered saline (PBS) for 15 min on ice, washed in PBS and 
incubated in 70% ethanol at −20°C overnight. After washing and incubation in DNA 
labeling solution containing TdT and bromodeoxyuridine (BrdU) triphosphates for 4 h at 
37°C, the cells were washed and incubated in staining buffer containing an Alexa Fluor 488 
dye-labelled anti-BrdU antibody for 30 min of incubation at room temperature, followed by 
addition of a PI/RNase mixture. After 30 min incubation at room temperature, TUNEL 
positivity and cell-cycle distribution were analysed with a BD FACSCalibur instrument (BD 
Biosciences, San Jose, CA, USA). The threshold for TUNEL positivity was determined as 
the maximal TUNEL signal observed in the untreated cells.
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Western blots
Whole-cell lysates were prepared in radioimmunoprecipitation assay (RIPA) buffer (Cell 
Signaling Tech, Danvers, MA, USA) with FOCUS™ ProteaseArrest™ (G-Biosciences, St. 
Louis, MO, USA) and Phosphatase Inhibitor Cocktail Set II (EMD Millipore, Billerica, MA, 
USA). Immunoblotting was performed with specific antibodies to TYK2, STAT1, phospho-
STAT1 (Tyr701), STAT3, phospho-STAT3 (Tyr705), STAT5, phospho-STAT5 (Tyr694), 
STAT6, phospho-STAT6 (Tyr641), AKT, phospho-AKT (Thr308), ERK1/2 (also termed 
MAPK3/MAPK1), phospho-ERK1/2 (Thr202/Tyr204), SAPK/JNK (also termed MAPK9/
MAPK8) (MAPK14), phospho-SAPK/JNK (Thr183/Tyr185), p38 MAPK (also termed 
MAPK14), phospho-p38 MAPK (Thr180/Tyr182), BCL2, BCLXL (also termed BCL2L11), 
MCL1, PARP and α-tubulin (all from Cell Signaling Tech).
T-ALL xenograft model
2 × 106 luciferase-expressing KOPT-K1 cells were injected into the tail vein of 7-week-old 
female NOD-SCID-IL2Rcγnull (NSG) mice (The Jackson Laboratory, Bar Harbor, ME, 
USA). The tumour burden was measured by bioluminescence imaging (BLI) every 7 days, 
using an IVIS Spectrum system (Caliper Life Sciences, Santa Clara, CA, USA). For each 
BLI time point, cancer bioluminescence was visualized by subcutaneous injection of d-
luciferin (Promega) in PBS at 75 mg/kg. After tumour engraftment was established by BLI 
measurement, mice were divided into 2 groups and treated by oral gavage either with vehicle 
control (20% HP-β-CD) or NDI-031301 at 100 mg/kg bid (twice daily) for 29 days. After 
completion of the treatment, 4 mice from each treatment group were sacrificed to obtain 
femur and spleen. The bone marrow cells were extracted from the femurs by crushing the 
bone in medium supplemented with 10% fetal bovine serum. The presence of human 
leukaemia cells was assessed by flow cytometric analysis following staining with fluorescein 
isothiocynate (FITC)-conjugated anti-human CD45 antibody (Biolegend, San Diego, CA, 
USA). The femur tissues were also fixed in 10% formalin, sectioned, paraffin-embedded and 
stained with haematoxylin and eosin. Stained slides were viewed and photographed using an 
Olympus BX41 microscope and Q-color5 digital camera (Olympus, Center Valley, PA, 
USA) and imaged with Adobe Photoshop CS4 software (Adobe, San Jose, CA, USA). 
Survival of the vehicle and NDI-031301 treated mice was defined from initiation of therapy 
until a moribund state was reached, and was analysed by the Kaplan-Meier method.
Statistical analysis
Statistical significance in assays with identical cell lines was assessed with Student’s t test 
(two-tailed). GraphPad Prism 6.02 (GraphPad Software) was used for all statistical analyses. 
The Calcusyn 2.0 software (Biosoft, Cambridge, UK) was used to analyse combined drug 
effects and produce the isobolograms normalized to the IC50 of each inhibitor.
Results
NDI-031301 is a potent and selective inhibitor of the TYK2 tyrosine kinase
Using a series of proprietary JAK family co-crystal structures in combination with a 
quantitative computational model to predict selectivity over the JAK family members, we 
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designed a series of selective TYK2 inhibitors (Wang, et al 2015). Elaboration of multiple 
hit series led to the identification of NDI-031301 as an inhibitor that is preferentially active 
against TYK2 compared to other JAK family kinases. Preclinical studies have illustrated that 
NDI-031301 potently inhibits targeted immune cell cytokine signalling and demonstrates 
outstanding efficacy in ameliorating disease in mouse models of psoriasis (Miao, et al 2015). 
The profile of NDI-031301, including the results of the biochemical TYK2 kinase assay, 
biochemical JAK family selectivity, plasma protein binding, and pharmacokinetic 
parameters in mice after oral administration are shown in Table I.
To assess the cellular activity and selectivity of NDI-031301 for TYK2, we tested its ability 
of this drug to inhibit the proliferation of Ba/F3 cells transformed by each of a series of 
constitutively active JAK family kinases (TEL-JAK1, TEL-JAK2, TEL-JAK3 and TEL-
TYK2) or by a more distantly related tyrosine kinase, TEL-ABL (Fig 1A). NDI-031301 
most strongly inhibited the growth of TYK2-transfomed cells, with the IC50 of 1.583 μM 
following 72 h of exposure, whereas Ba/F3 cells transformed by other tyrosine kinases 
showed decreased sensitivity to this drug (Fig 1D). Tofacitinib (JAK1, JAK2 and JAK3 
inhibitor) and baricitinib (JAK1 and JAK2 inhibitor) were less effective inhibitors than 
NDI-031301 on the proliferation of TYK2-transformed cells, with IC50 values of 23.89 μM 
(tofacitinib) and 3.98 μM (baricitinib) after 72 h of treatment, while these drugs were highly 
active against Ba/F3 cells transformed by the other JAK family kinases (Fig 1B, C and D). 
These results demonstrate that NDI-031301 is a selective inhibitor of TYK2 tyrosine kinase 
with activity in cells transduced and rendered IL-3-independent by an activated form of this 
kinase.
NDI-031301 induces growth inhibition and apoptosis in human T-ALL cell lines
To assess the anti-tumour potency of NDI-031301 against T-ALL, we tested the inhibitory 
effect of this drug on the proliferation of multiple T-ALL cell lines (Fig 2A). This agent 
induced remarkable cytotoxicity in each of 4 human T-ALL cell lines representing different 
molecular subtypes of the disease (DU.528, KOPT-K1, HPB-ALL and SKW-3), with IC50 
values of 0.8186 – 2.38 μM after 72 h of exposure (Fig 2D). This inhibitory effect was more 
potent than that of either tofacitinib or baricitinib, except that DU.528 cells were highly 
sensitive to all JAK kinase inhibitors tested in this study (Fig 2B, C and D). To gain insight 
into the cytotoxic mechanism triggered by NDI-031301, we next monitored changes in the 
relative numbers of KOPT-K1 cells treated with NDI-031301 over a 5-day period. As shown 
in Figure 2E, DMSO-treated KOPT-K1 cells demonstrated exponential growth while 
NDI-031301 treatment demonstrated dose-dependent growth suppression, with 1 μM 
NDI-031301 causing minor growth suppression of KOPTK1 cells and 3 μM NDI-031301 
treatment reducing total cell number 8-fold on the fifth day of treatment, as compared to cell 
numbers at Day 0. Moreover, we demonstrated that NDI-031301 caused a profound 
apoptotic response in the KOPT-K1 cells, as shown by the appearance of 31.1% apoptotic 
cells following treatment with 3μM NDI-031301 for 48 h in a TUNEL apoptotic assay (Fig 
2F). An increased level of apoptosis in KOPT-K1 cells was also observed at 24 h after 
treatment with 3 μM NDI-031301 by flow cytometric analysis following Annexin V-FITC 
and PI double staining (Fig S1).
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TYK2 inhibition leads not only to suppression of STAT1 phosphorylation, but also 
activation of MAPK signalling pathways in KOPT-K1 cells
Our previous results indicated that TYK2 acts to upregulate levels of the anti-apoptotic 
protein BCL2 in T-ALL cells through phosphorylation and activation of STAT1 (Sanda, et al 
2013). However, this is not the only pathway involved in TYK2-mediated promotion of 
survival, because a specific inhibitor of BCL2, ABT-199, is not active in the killing of most 
T-ALL cells (Anderson, et al 2014, Chonghaile, et al 2014, Peirs, et al 2014). Rather, only T-
ALL cells with an early T-cell progenitor (ETP) phenotype show enhanced sensitivity to 
ABT-199 (Anderson, et al 2014, Chonghaile, et al 2014, Peirs, et al 2014), implying that 
other mechanisms in addition to the downregulation of the STAT1-BCL2 signalling 
contribute to the induction of apoptosis by TYK2 inhibition. Thus, we investigated cellular 
signalling pathways that are associated with cell survival and specifically affected by TYK2 
inhibition with NDI-031301. We treated KOPT-K1 cells with NDI-031301, tofacitinib, or 
baricitinib for 24 h, and then examined the levels of total and phosphorylated protein of 
known cell survival signalling pathways (Fig 3A). Two drug concentrations, 1 μM and 3 μM, 
of NDI-031301 were selected for this assay because this compound had produced a dose-
dependent inhibitory effect on TYK2-transformed Ba/F3 cells (Fig 1A) as well as KOPT-K1 
cells (Fig 2A) over this concentration range. The concentrations of tofacitinib (1 μM) and 
baricitinib (300 nM) were determined from the results of the Ba/F3 assay, in which these 
concentrations efficiently inhibited the proliferation of Ba/F3 cells transformed by 
corresponding JAK kinases, without affecting the viability of TYK2-transformed cells (Fig 
1B and C).
The results in Figure 3A indicate that treatment with 3 μM of NDI-031301 leads to reduction 
of STAT1 Tyr-701 phosphorylation and BCL2 protein levels in KOPT-K1 cells, consistent 
with our previous finding that TYK2 phosphorylates STAT1 and upregulates BCL2 
expression in most T-ALL cells (Sanda, et al 2013). Decreased levels of STAT1 Tyr-701 
phosphorylation were also observed in cells treated with tofacitinib or baricitinib, 
demonstrating that this activity is not specific to TYK2 inhibition and that other JAK kinases 
are involved in the regulation of STAT1 Tyr-701 phosphorylation in KOPT-K1 cells. The 
phosphorylation levels of STAT3 (Tyr-705), STAT5 (Tyr-694) and STAT6 (Tyr-641) were 
not affected by treatment with either NDI-031301 or other JAK kinase inhibitors (Fig 3A). 
The levels of AKT Thr-308 phosphorylation were also unchanged after each of the 
treatments (Fig 3A). We found that each of the mitogen-activated protein kinase (MAPK) 
pathways were activated specifically by treatment with 3 μM of NDI-031301, as indicated 
by increased phosphorylation levels of ERK1/2 (Thr-202/Tyr-204), SAPK/JNK (Thr-183/
Tyr-185), and p38 MAPK (Thr-180/Tyr-182) (Fig 3A). Importantly, efficient induction of 
apoptosis was observed only in the cells treated with 3 μM of NDI-031301, as indicated by 
the presence of cleaved PARP (Fig 3A). These results indicate that downregulation of 
STAT1 Tyr-701 phosphorylation is not sufficient by itself to induce apoptosis in KOPT-K1 
cells, suggesting instead that activation of the MAPK pathways might also play a role in 
NDI-031301-induced apoptosis in these cells.
We then asked whether the effect of NDI-031301 on cellular signalling could be 
recapitulated by gene knockdown of TYK2. Silencing of TYK2 by lentiviral shRNA 
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knockdown (shTYK2 2 and 3) resulted in elimination of STAT1 Tyr-701 phosphorylation in 
KOPT-K1 cells (Fig 3B), consistent with the result in the cells treated with NDI-031301 (Fig 
3A). The increased phosphorylation levels of SAPK/JNK (Thr-183/Tyr-185) and p38 MAPK 
(Thr-180/Tyr-182) were clearly observed in the cells transfected with TYK2-targeting 
shRNAs, while the levels of ERK1/2 phosphorylation (Thr-202/Tyr-204) were not 
upregulated (Fig 3B). Thus, TYK2 signalling is required for the down-modulation of the 
SAPK/JNK and p38 MAPK pathways in KOPT-K1 cells, as indicated both genetically and 
by NDI-031301-mediated inhibition of TYK2 tyrosine kinase activity.
Activation of p38 MAPK is involved in NDI-031301-induced apoptosis in KOPT-K1 cells
Previous studies have shown that the SAPK/JNK and p38 MAPK pathways play key roles in 
the negative selection of CD4+/CD8+ thymocytes (Rincon and Davis 2009, Sohn, et al 2003, 
Sohn, et al 2007, Sugawara, et al 1998, Tanaka, et al 2002), an essential process by which 
self-reactive T-cells are removed from the host. Thus, we hypothesized that activated MAPK 
pathways are also involved in NDI-031301-mediated apoptosis in T-ALL cells. Time-course 
analyses with KOPT-K1 cells demonstrated that a dramatic increase in levels of p38 MAPK 
phosphorylation (Thr-180/Tyr-182) and a decrease in levels of STAT1 phosphorylation 
(Tyr-701) occurred at 1 h after treatment with 3 μM of NDI-031301, while increased levels 
of ERK1/2 Thr-202/Tyr-204 and SAPK/JNK Thr-183/Tyr-185 phosphorylation were 
observed after 8 h of treatment (Fig 4A). Cleaved PARP was first detected at 12 h of 
treatment (Fig 4A). These results indicate that NDI-031301 mediates activation of the 
MAPK pathways before the induction of apoptosis.
We next determined whether pharmacological inhibition of each MAPK pathway could 
protect T-ALL cells from proliferative suppression and apoptosis induced by NDI-031301. 
We treated KOPT-K1 cells for 72 h with 0 to 3 μM of NDI-031301 in combination with each 
of the following MAPK pathway inhibitors: SB203580 (p38 MAPK inhibitor; 0, 5 and 10 
μM), trametinib (MEK1/2 inhibitor; 0, 1.25 and 2.5 nM) and SP600125 (SAPK/JNK 
inhibitor; 0 and 5 μM), and then assessed the cell proliferative responses. We found that 
combined treatment with SB203580 partially rescued the NDI-031301-induced decrease of 
viability in KOPT-K1 cells (Fig 4B). Isobologram analysis indicated that this combination 
produced remarkable antagonism between the two inhibitors in decreasing cell viability, as 
indicated by the average combination index (CI) value of 2.06 (Fig 4C). Combination with 
trametinib or SP600125 showed no rescue effects on the viability of KOPT-K1 cells treated 
with NDI-031301 (Fig S2A and C) with only modest antagonism for combination with 
trametinib (average CIs: 1.39) (Fig S2B) or SP600125 (average CIs: 1.15) (Fig S2D). 
SB203580 also partially rescued NDI-031301-induced apoptosis in KOPT-K1 cells, as 
indicated by a decrease in TUNEL positivity (Fig 4D), and an absence or decreased levels of 
cleaved PARP induced by 3 μM of NDI-031301 (Fig 4E). We also found that SB203580 
efficiently inhibited NDI-031301-mediated increase of levels of p38 MAPK Thr-180/
Tyr-182 phosphorylation without downregulating the levels of ERK1/2 Thr-202/Tyr-204 and 
SAPK/JNK Thr-183/Tyr-185 phosphorylation (Fig 4E). These results demonstrate that 
activation of the p38 MAPK pathway, but not the ERK or SAPK/JNK pathways, is at least 
partially responsible for NDI-031301-induced apoptosis in KOPT-K1 cells, indicating 
involvement of the p38 MAPK pathway in TYK2-mediated survival in T-ALL cells. Further 
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investigation to assess NDI-031301 sensitivity and the effect of the drug treatment on 
cellular signalling pathways in an additional 3 T-ALL cell lines indicated variable levels of 
increased phosphorylation of p38 MAPK and downregulation of BCL2 that did not clearly 
correlate with the IC50 values for NDI-031301 in these cell lines (Fig S3A-D). Thus, there 
appears to be considerable heterogeneity in altered signal transduction in the different cell 
lines after treatment with NDI-031301 in the timing and magnitude of the response, which is 
expected given the wide heterogeneity of oncogenic mutations and chromosomal 
abnormalities among these T-ALL cell lines.
NDI-031301 suppresses the proliferation of T-ALL cells in vivo
We then tested the efficacy of NDI-031301 in vivo using a murine xenograft model. By 
injecting NSG mice with 2 × 106 KOPT-K1 cells expressing luciferase, we were able to 
quantify leukaemia growth by BLI. Once tumour engraftment was established by BLI (Fig 
5A), treatment with either vehicle or 100 mg/kg NDI-031301 twice daily was initiated and 
continued for 29 days. This dosage of NDI-031301 was well tolerated by the mice without 
any appreciable side effects and body weight loss (Fig S4). We found that treatment with 
NDI-031301 significantly delayed tumour progression in this model (Fig 5B and C): mean 
bioluminescence on day 42 was 3.126 × 1010/photons (ph)/s/cm2/steradian (sr) for vehicle 
control, versus 1.277 × 1010/ph/s/cm2/sr for NDI-031301-treated animals (P < 0.0001; n = 6 
in each group). As a result, NDI-031301 significantly increased overall survival compared 
with vehicle treatment (P = 0.0064; n = 6 in each group) (Fig 5D).
After 29 days of treatment, mice receiving NDI-031301 had marked reductions in 
splenomegaly by comparison with controls (Fig 6A and B). Flow cytometric analysis to 
detect human CD45-positive cells showed a significant decrease in the extent of leukaemic 
cell infiltration in the femur bone marrow of NDI-031301-treated mice versus vehicle-
treated mice (Fig 6C and D). Decreased numbers of human leukaemia cells after 
NDI-031301 treatment were also observed in the peripheral blood (Fig S5). 
Histopathological analysis of the bone marrow of the vehicle-treated mice showed massive 
infiltration by leukaemic cells (Fig 6E), while NDI-031301 treatment suppressed leukaemic 
cell infiltration (Fig 6F). Taken together, our results demonstrate that NDI-031301 is 
efficacious in delaying the growth of human T-ALL cells in vivo and in extending the 
survival of mice bearing human T-ALL cells.
Discussion
Here we report that TYK2 inhibition by a small-molecule inhibitor, NDI-031301, results in 
robust anti-tumour activity in T-ALL cells. We found that NDI-031301 shows selective 
inhibitory activity against TYK2 as compared to other JAK kinases in living cells, as 
indicated by transformed Ba/F3 assays. This inhibitor induced cytotoxicity in 4 
representative human T-ALL cell lines, consistent with our previous result showing the 
growth and survival inhibition of these cells by silencing TYK2 with shRNA (Sanda, et al 
2013). Finally, the anti-leukaemic activity of NDI-031301 was recapitulated in a KOPT-K1 
in vivo xenograft study, indicating that this inhibitor is able to efficiently suppress the 
growth of human T-ALL cells in vivo as well as in vitro.
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Our results also indicated that in the KOPT-K1 T-ALL cell line, activation of three different 
MAPK signalling pathways was observed after treatment with NDI-031301. However, of 
these pathways, only the activation of p38 MAPK contributed to apoptosis induced by this 
inhibitor. Increased phosphorylation levels of p38 MAPK (Thr-180/Tyr-182) were also 
observed in the cells transfected with each of two different shRNAs targeting TYK2 (Fig 
3B), indicating that NDI-031301-mediated activation of p38 MAPK is probably mediated 
through inhibition of TYK2. Time-course analyses with KOPT-K1 cells demonstrated 
elevated levels of p38 MAPK phosphorylation (Thr-180/Tyr-182), as observed at 1 h post-
treatment with NDI-031301, suggesting that TYK2 negatively regulates proteins that control 
the activation of p38 MAPK in T-ALL cells. Previous studies have shown a critical role for 
p38 MAPK pathway activation in the anti-leukaemic effects of dasatinib (Dumka, et al 
2009), imatinib (Parmar, et al 2004) and IFNα (Mayer, et al 2001) in BCR-ABL-
transformed cells; however, our finding is the first to demonstrate involvement of p38 
MAPK pathway activation in T-ALL cell death occurring after TYK2 inhibition. We did not 
find clear association between variable levels of phosphorylation of p38 MAPK and 
differential NDI-031301 sensitivities in human T-ALL cell lines (Fig 4A and Fig S3A-D), 
suggesting that the consequences of p38 MAPK activation are highly context-dependent and 
probably differ based on the wide genetic and phenotypic heterogeneity among individual T-
ALL cases. Importantly, activation of p38 MAPK is associated with the deletion of 
CD4+CD8+ double-positive thymocytes by negative selection (Rincon and Davis 2009, 
Sohn, et al 2003, Sohn, et al 2007, Sugawara, et al 1998, Tanaka, et al 2002), although the 
mechanism of this effect still remains to be established. It is conceivable that TYK2 
normally promotes the survival of a subset of developing thymocytes, and that this pathway 
becomes essential for the survival of transformed T-ALL cells.
Our findings clearly support TYK2 inhibition with NDI-031301 or a related compound as a 
potential therapeutic strategy for patients with T-ALL, and also raise the possibility that 
enhancing p38 MAPK activation in T-ALL cells may be an approach to accentuate its anti-
leukaemic activity. Further preclinical studies with selective TYK2 inhibitors, both alone 
and in combination with other targeted inhibitors, are needed to delineate an optimal strategy 
for targeting this pathway, which will be essential for the design of early stage clinical trials 
to incorporate TYK2 inhibition into available regimens for the treatment of patients with T-
ALL.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig 1. NDI-031301 is a potent and selective inhibitor of TYK2 tyrosine kinase
(A-C) Anti-proliferative activity of NDI-031301 (A), tofacitinib (B) or baricitinib (C) on 
transformed Ba/F3 cells. Ba/F3 cells transformed by TEL-ABL, TEL-JAK1, TEL-JAK2, 
TEL-JAK3, or TEL-TYK2 were cultured with graded concentrations of the indicated 
inhibitor for 72 h. Cell viability values are mean ± s.d. percentages of the untreated control 
value in triplicate experiments. (D) 50% inhibitory concentration (IC50) values for 
NDI-031301, tofacitinib and baricitinib in Fig 1A-C.
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Fig 2. NDI-031301 induces growth inhibition and apoptosis in human T-ALL cell lines
(A-C) Anti-proliferative activity of NDI-031301 (A), tofacitinib (B), or baricitinib (C) on 
human T-ALL cell lines. DU.528, KOPT-K1, HPB-ALL and SKW-3 cells were cultured 
with graded concentrations of the indicated inhibitor for 72 h. Cell viability values are mean 
± s.d. percentages of the untreated control value in triplicate experiments. (D) 50% 
inhibitory concentration (IC50) values for NDI-031301, tofacitinib and baricitinib in Fig 2A-
C. (E) KOPT-K1 cells were cultured in 0, 1 μM, or 3 μM of NDI-031301, and the number of 
viable cells was measured with trypan blue staining. Values are mean ± s.d. fold changes 
relative to Day 0 in triplicate experiments. * P < 0.05; ** P < 0.01; *** P < 0.001 by two-
sample, two-tailed t test. (F) KOPT-K1 cells were cultured in 0, 1 μM, or 3 μM of 
NDI-031301 for 48 h. Cells were fixed, and assessed for apoptosis and cell-cycle 
distribution by flow cytometric analysis after terminal deoxynucleotidyl transferase (TdT) 
dUTP nick-end labeling (TUNEL) and proppidium iodide (PI) double labelling. The panels 
show two-dimensional dot plots with the percentage of TUNEL-positive cells in each 
sample.
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Fig 3. TYK2 inhibition leads to activation of the MAPK signalling pathways as well as 
downregulation of phospho-STAT1 in KOPT-K1 cells
(A) Western blot analysis to assess the effect of each JAK kinase inhibitor on cellular 
signalling pathways in KOPT-K1 cells. KOPT-K1 cells were treated with the indicated 
concentrations of NDI-031301, tofacitinib or baricitinib for 24 h, and subjected to 
immunoblot analysis with each specified antibody. (B) KOPT-K1 cells were lentivirally 
transduced with TYK2-targeting shRNAs (shTYK2 2 and 3) or control shRNAs targeting 
GFP (shGFP) or luciferase (shLuc). Whole-cell extracts were analyzed by immunoblotting 
with each specified antibody.
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Fig 4. Activation of p38 MAPK is involved in NDI-031301-induced apoptosis in KOPT-K1 cells
(A) Time-course analysis to assess the effect of NDI-031301 on cellular signalling pathways 
in KOPT-K1 cells. The cells were treated with dimethyl sulfoxide (DMSO) or 3 μM of 
NDI-031301, and harvested at the indicated times. Western blot analysis was conducted with 
each specified antibody. (B-C) KOPT-K1 cells were treated for 72 h with serial dilutions of 
NDI-031301 (0 - 3 μM) and p38 MAPK pathway inhibitor SB203580 (0 - 10 μM) in 
combination. Relative cell viability is shown in panel (B), as mean ± s.d. percentages of the 
DMSO-treated control value in triplicate experiment. The normalized isobologram was 
obtained with the Calcusyn software. The combination index (CI) was plotted as a function 
of dose combination and an average CI of the drug combination is indicated in panel (C). 
The additive isobole is depicted as a straight line, with antagonistic dose combinations 
labelled above the isobole. An average CI of 1 indicates an additive effect, CI < 1 is 
synergistic and CI > 1 antagonistic. (D) KOPT-K1 cells were cultured for 48 h with DMSO 
or 3 μM of NDI-031301 in the absence or presence of SB203580 (5 or 10 μM). Cells were 
fixed and assessed for apoptosis by flow cytometric analysis following terminal 
deoxynucleotidyl transferase (TdT) dUTP nick-end labeling (TUNEL) and proppidium 
iodide (PI) double staining. Upper panels show two-dimensional dot plots with the 
percentage of TUNEL-positive cells in each treated sample. Lower panel shows 
quantification of TUNEL-positive cells. Values represent mean ± s.d. percentages of 
TUNEL-positive cells in duplicate experiments. *: P < 0.05 by two-sample, two-tailed t test. 
(E) SB203580 inhibits activation of p38 MAPK and apoptosis induced by NDI-031301. 
KOPT-K1 cells were cultured for 24 h with DMSO or 3 μM of NDI-031301 in the absence 
or presence of SB203580 (5 or 10 μM). Whole-cell extracts were analyzed by 
immunoblotting with each specific antibody.
Akahane et al. Page 17
Br J Haematol. Author manuscript; available in PMC 2018 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig 5. NDI-031301 treatment effectively suppresses the growth of KOPT-K1 cells engrafted into 
NSG mice and provides a significant survival benefit
(A) Bioluminescent images of two representative mice to be treated with either vehicle or 
NDI-031301, on day 0. Scale bar indicates the bioluminescence intensities. (B) 
Bioluminescent images of representative mice treated with either vehicle or 100 mg/kg 
NDI-031301 twice daily for the indicated number of days. Scale bar shows the colour 
variation corresponding to bioluminescence intensities. (C) Mean ± SEM bioluminescence 
of mice treated with vehicle or 100 mg/kg NDI-031301 for 29 days (n = 6 for each treatment 
group; statistical significance was assessed at day 42 by two-sample, two-tailed t test). (D) 
Kaplan-Meier survival analysis of mice treated with vehicle or 100 mg/kg NDI-031301 for 
29 days (n = 6 for each treatment group; statistical significance was assessed with the log-
rank test).
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Fig 6. NDI-031301 reduces infiltration of leukaemia cells into mouse bone marrow and spleen
All samples were harvested on Day 29 after twice daily treatment with vehicle or 100 mg/kg 
NDI-031301 for 29 days. (A) A photograph of spleens from representative mice. Ruler scale 
is in cm. (B) Spleen weights. Error bars represent SEM. Statistical significance was assessed 
by two-sample, two-tailed t test. (C) Human CD45-FITC histogram of femur bone marrow 
cells in a representative mouse. The percentage of human CD45-positive cells is shown in 
each panel. (D) Total numbers of human CD45-positive cells in a femur of each treated 
mouse (n = 4 for each treatment group). Error bars represent SEM. Statistical significance 
was assessed by two-sample, two-tailed t test. (E-F) Haematoxylin and eosin staining of 
paraffin-embedded femur sections isolated from mice treated with vehicle (E) or 100 mg/kg 
NDI-031301 (F).
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Table I
Potency, JAK family selectivity, and pharmacokinetics of NDI-031301.
Potency, Selectivity and Drug-like Properties* NDI-031301
Biochemical TYK2 Kinase Assay
at 1 mM ATP (nM) TYK2 Ki 130
Biochemical JAK Family Kinase
Activity at 1 mM ATP (nM)
JAK1 Ki 2200
JAK2 Ki 2750
JAK3 Ki 2480
Cell Growth Inhibition GIC50 (μM) KOPT-K1 cells 2
PPB mouse PPB (% bound) 76
Mouse PK
PO 100 mg/kg
T1/2 (h) 4.9
Cmax (μM) 25
Ki, kinase inhibitor; GIC50, 50% growth inhibitory concentration; PK, pharmacokinetics; PPB, plasma protein binding
*
In vivo pharmacokinetic profiles of NDI-031301 in mice (C57) treated with indicated doses of inhibitor. Half-life (T1/2) and maximum serum 
concentration (Cmax) of the drug concentration-time profile are shown.
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